News Pfizer's new drug data in breast cancer draws muted response Pfizer and Arvinas' much-anticipated oral SERD vepdegestrant for breast cancer missed a key endpoint in its first phase 3 readout.
News Data cues up AZ oral SERD filing in first-line breast cancer AstraZeneca could be the first to bring an oral SERD to market in first-line breast cancer after camizestrant hit the mark in a phase 3 trial.
News NHS trial puts AI for breast cancer screening under scrutiny Nearly 700,000 women will be recruited into an NHS trial of AI tools for breast cancer screening, in the hope of relieving pressure on radiologists.
News Boost to Enhertu's prospects as FDA clears Roche diagnostic Roche gets the first FDA approval for a diagnostic test for HER2-ultralow breast cancer, now on the label of AstraZeneca and Daiichi Sankyo's Enhertu.
News Enhertu gets first okay for HER2-ultralow breast cancer Enhertu gets much-anticipated new FDA approval in breast cancer that expands its label and makes it an earlier option in the treatment pathway.
News AZ, Daiichi get FDA nod for Dato-DXd in breast cancer AstraZeneca and Daiichi Sankyo have claimed FDA approval for a second antibody-drug conjugate for breast cancer - TROP2-directed Datroway.
News FDA chooses flu vaccine strains despite cancelled meeting The FDA has released its recommendations on the composition of influenza vaccines for the 2025-26 season – without the input of its external advisors.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
